source
- Pharma faces $500B risk as patents expire, with Merck most exposed by 2028More than $500 billion in global prescription sales could be threatened by generic competition between 2026 and 2032, according to Norstella data cited by Evaluate. Merck is the most immediately e…
- BMS reports Phase 3 success for RYZ101 in GEP-NET trialBristol Myers Squibb said its radiopharmaceutical candidate RYZ101 met the primary endpoint in a late‑stage Phase 3 study. The drug was acquired in BMS's $4.1 billion purchase of RayzeBio, complete…